An Early Phase 1 interventional study of Placebo and Salsalate 750 MG Oral Tablet [DISALCID] in Electronic Cigarette Use, Endothelial Dysfunction and Inflammation, sponsored by University of Iowa. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Iowa · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.
Among the 288 studies in Vaping with a site in United States, this one is the 210th largest by planned enrollment of the 258 interventional ones that give a count, is one of 31 that started in 2024, is one of 16 in phase 1, reaches primary completion later than 27 of the 73 other live ones, and was the 220th registered.
404 studies on the registry are indexed under Vaping; 97 are open to participants now.
Browse Vaping studies →66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of Nebraska · Sites in United States
Ages 15–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 24 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
288 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 21 · Phase 3 4 · Phase 4 12
First in 2013; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 79 across 324 interventional studies indexed under Vaping.
Median enrollment 71 across the 258 interventional studies, 110 across the 30 observational. Of the 202 that completed or were terminated, 87 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 288 have an industry lead sponsor. The 10 most frequent:
University of Iowa is the lead sponsor of 279 studies on the registry; 32 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 40 (89%) have results posted.
University of Iowa has 1 study filed under Vaping — fewer than ten, so there is no comparison to draw.
31 of the studies in Vaping with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06159608Anna Stanhewicz, PhDSex Differences in the Vascular Effects of E-cigarette Use | 2026-12 |
| NCT04661683University of California, Los AngelesSecondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol | 2026-12-15 |
| NCT07553585Yale UniversitySurvey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes | 2026-12-15 |
| NCT04907136Florida International UniversityDeveloping and Testing Health Warning Labels on the ENDS Device | 2026-12-30 |
Add all 31 to your calendar (.ics) → With an account.
Among the 288 studies in Vaping with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo oral table twice daily for 4 days prior to experimental testing followed by 14 day washout period and then salsalate oral tablet 1500mg twice daily for 4 days prior to experimental testing.
Drug: Placebo · Drug: Salsalate 750 MG Oral Tablet [DISALCID]
Salsalate oral tablet 1500mg twice daily for 4 days prior to experimental testing followed by 14 day washout period and then placebo oral tablet twice daily for 4 days prior to experimental testing.
Drug: Placebo · Drug: Salsalate 750 MG Oral Tablet [DISALCID]
Oral placebo tablet
Oral salsalate tablet
Microvascular endothelial function (Cutaneous conductance, %maximum) following salsalate treatment compared to placebo treatment
Endothelium-dependent vasodilation assessed as cutaneous conductance response (cutaneous conductance = local red blood cell flux/mean arterial pressure; %maximum) to local heating of the skin (42 degrees Celcius).
Time frame: a total of 2 times throughout the study (approximately 4 weeks): 1) at the completion of 4 days of oral salsalate treatment, and 2) at the completion of 4 days of placebo treatment
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2026 → Apr 2027 and completion Oct 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Salicylsalicylic acid